Rotavirus VP6 Specific Human IgA Antibodies
轮状病毒 VP6 特异性人类 IgA 抗体
基本信息
- 批准号:7707817
- 负责人:
- 金额:$ 23.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-22 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntibodiesAntibody FormationAntiviral AgentsApicalAttenuated Live Virus VaccineBindingBiological AssayBispecific AntibodiesCellsCellular biologyChildClinical TrialsComplexDiarrheaDiseaseEndocytosisEndosomesEpithelial CellsGenetic TranscriptionGoalsHumanHuman CloningHuman VirusIgA receptorIgG1ImmuneImmune responseImmunityImmunoglobulin AIntestinesKnowledgeLengthMediatingMethodsPhysiologicalPolymeric Immunoglobulin ReceptorsProteinsRecombinant AntibodyRecombinantsRecyclingRoleRotavirusRotavirus InfectionsSolidSpecific qualifier valueSystemTechnologyTestingTranscriptVaccinesViralViral AntibodiesViral ProteinsVirusVirus DiseasesWorkhuman monoclonal antibodiesinhibiting antibodyinhibitor/antagonistkillingsmeetingsnovelparticlepathogenpolarized cellpolymeric IgAtraffickingtranscytosisvariable region gene
项目摘要
DESCRIPTION (provided by applicant): Mechanisms of immunity to rotavirus, the major cause of dehydrating diarrhea in children, have proven elusive. Despite the fact the live attenuated vaccines induce protection against severe disease, we still don't understand fully how immunity to rotavirus works, or even have rock-solid correlates of immunity from clinical trials. Animal models have suggested a variety of contributing mechanisms. Conceptually, understanding intestinal immunity to rotavirus is very important, because rotavirus represents a prototypical viral infection of humans that is limited to the intestine. If we can understand mucosal immune mechanisms to rotavirus, we will understand a lot more about immunity in the gut that is relevant to a plethora of pathogens. We hypothesize that a dominant mechanism of rotavirus inhibition by the human immune response is rotavirus specific virus protein 6 (VP6) specific antibodies of the IgA isotype. We propose that polymeric VP6-specific IgA antibodies bind to double layered particles inside infected intestinal cells and inhibit viral transcription. This mechanism has never really been tested in clinical trials as a correlate or mechanism, because VP6-specific antibodies will not neutralize virus in a conventional inhibitory assay, and only IgA antibodies could mediate the effect during transcytosis in polarized cells. We have isolated a large panel of hundreds of human VP6-specific human monoclonal antibodies, and shown that the immunodominant antibody response of humans specifies a set of antibodies that bind to double layered particles at the point of five-fold symmetry, inhibiting egress of viral transcripts from the transcriptionally active particle. The goal of this application is to show 1) that polymeric IgA forms of these antibodies inhibit rotavirus in a physiological manner during basolateral to apical transcytosis, 2) that the apical recycling endosome is a critical part of the transycytotic mechanism related to inhibition, and 3) that we can develop an artificial bispecific antibody scFv construct that can deliver antiviral antibodies to the cell via the IgA receptor (pIgR) as a means of developing biologic inhibitors for use against any intracellular intestinal pathogen. The work in this application will study the role of a particular type of antibodies in the gut (IgA antibodies) on immunity to rotavirus, the most common cause of severe diarrhea in children. The work seeks to show that these special antibodies bind to "inside" parts of the virus when the virus and antibodies meet inside of infected cells in the gut. If we show that this method of killing virus does inhibit rotavirus, we will understand how rotavirus antibodies and vaccines work and we can use this knowledge to create vaccines that work in a similar manner against other pathogens.
描述(由申请人提供):轮状病毒的免疫机制,儿童脱水腹泻的主要原因,已被证明是难以捉摸的。尽管减毒活疫苗可以预防严重疾病,但我们仍然不完全了解对轮状病毒的免疫力是如何起作用的,甚至没有从临床试验中获得可靠的免疫力相关性。动物模型表明了多种作用机制。从概念上讲,了解肠道对轮状病毒的免疫是非常重要的,因为轮状病毒代表了一种仅限于肠道的人类典型病毒感染。如果我们能了解轮状病毒的粘膜免疫机制,我们就能更多地了解肠道中与大量病原体相关的免疫系统。我们假设轮状病毒被人类免疫反应抑制的主要机制是IgA同型的轮状病毒特异性病毒蛋白6 (VP6)特异性抗体。我们提出聚合vp6特异性IgA抗体与感染肠细胞内的双层颗粒结合并抑制病毒转录。这种机制从未在临床试验中作为一种相关性或机制进行过真正的测试,因为vp6特异性抗体在传统的抑制实验中不会中和病毒,只有IgA抗体可以在极化细胞的胞吞作用中介导作用。我们已经分离了数百个人类vp6特异性人类单克隆抗体,并表明人类的免疫优势抗体反应指定了一组抗体,这些抗体在五重对称点与双层颗粒结合,抑制转录活性颗粒的病毒转录本的输出。本应用程序的目的是表明1)这些抗体的聚合IgA形式在基底外侧到根尖的胞吞过程中以生理方式抑制轮状病毒,2)根尖循环内体是与抑制相关的胞吞机制的关键部分。3)我们可以开发一种人工双特异性抗体scFv结构,它可以通过IgA受体(pIgR)将抗病毒抗体传递到细胞中,作为开发生物抑制剂的一种手段,用于对抗任何细胞内肠道病原体。这项应用将研究肠道中一种特殊类型的抗体(IgA抗体)对轮状病毒免疫的作用,轮状病毒是儿童严重腹泻的最常见原因。这项研究试图证明,当病毒和抗体在肠道内被感染的细胞内相遇时,这些特殊的抗体会结合到病毒的“内部”部分。如果我们证明这种杀死病毒的方法确实能抑制轮状病毒,我们将了解轮状病毒抗体和疫苗是如何起作用的,我们可以利用这些知识制造出以类似方式对抗其他病原体的疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James E Crowe其他文献
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
呼吸道合胞病毒预防触手可及:疫苗和单克隆抗体的现状
- DOI:
10.1016/s1473-3099(22)00291-2 - 发表时间:
2023-01-01 - 期刊:
- 影响因子:31.000
- 作者:
Natalie I Mazur;Jonne Terstappen;Ranju Baral;Azucena Bardají;Philippe Beutels;Ursula J Buchholz;Cheryl Cohen;James E Crowe;Clare L Cutland;Linda Eckert;Daniel Feikin;Tiffany Fitzpatrick;Youyi Fong;Barney S Graham;Terho Heikkinen;Deborah Higgins;Siddhivinayak Hirve;Keith P Klugman;Leyla Kragten-Tabatabaie;Philippe Lemey;Louis Bont - 通讯作者:
Louis Bont
James E Crowe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James E Crowe', 18)}}的其他基金
Human Monoclonal Antibodies for Encephalitic Alphaviruses
脑炎甲病毒的人单克隆抗体
- 批准号:
10539155 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Human Monoclonal Antibodies for Encephalitic Alphaviruses
脑炎甲病毒的人单克隆抗体
- 批准号:
10669266 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Structure based design of trimer interface epitope focused universal influenza vaccines
基于三聚体界面表位的通用流感疫苗的结构设计
- 批准号:
10361516 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
Structure based design of trimer interface epitope focused universal influenza vaccines
基于三聚体界面表位的通用流感疫苗的结构设计
- 批准号:
10576343 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
B-Cell Epitope Discovery and Mechanisms of Antibody Protection: Genetic and Structural Basis for Virus Neutralization
B 细胞表位发现和抗体保护机制:病毒中和的遗传和结构基础
- 批准号:
10021075 - 财政年份:2019
- 资助金额:
$ 23.25万 - 项目类别:
Research Project 2: Therapeutic Human Monoclonal Antibody Treatments for Filoviruses
研究项目2:丝状病毒的治疗性人单克隆抗体治疗
- 批准号:
10576280 - 财政年份:2019
- 资助金额:
$ 23.25万 - 项目类别:
Functional Antibody Repertoire Against S. aureus Leukocidins after Invasive Human Infection
人类侵袭性感染后针对金黄色葡萄球菌杀白细胞素的功能性抗体库
- 批准号:
10541163 - 财政年份:2019
- 资助金额:
$ 23.25万 - 项目类别:
B-Cell Epitope Discovery and Mechanisms of Antibody Protection: Genetic and Structural Basis for Influenza Neutralization
B 细胞表位发现和抗体保护机制:流感中和的遗传和结构基础
- 批准号:
10669544 - 财政年份:2019
- 资助金额:
$ 23.25万 - 项目类别:
B-Cell Epitope Discovery and Mechanisms of Antibody Protection: Genetic and Structural Basis for Influenza Neutralization
B 细胞表位发现和抗体保护机制:流感中和的遗传和结构基础
- 批准号:
10903692 - 财政年份:2019
- 资助金额:
$ 23.25万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 23.25万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:














{{item.name}}会员




